---
title: "HANGZHOU LANDSCAPING: There are no significant matters and risk matters that should be disclosed but have not been disclosed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/231194323.md"
description: "HANGZHOU LANDSCAPING announced that the closing price of its stock on March 7 and March 10, 2025, had a cumulative deviation of over 20% in price increase over two consecutive trading days. According to the relevant provisions of the \"Shanghai Stock Exchange Trading Rules,\" this constitutes an abnormal fluctuation in stock trading. After the company's self-examination and written verification with the controlling shareholder and actual controller, as of the date of this announcement, the company has no significant matters or risk matters that should be disclosed but have not been disclosed"
datetime: "2025-03-10T09:42:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/231194323.md)
  - [en](https://longbridge.com/en/news/231194323.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/231194323.md)
generator: "portal-rs"
---

# HANGZHOU LANDSCAPING: There are no significant matters and risk matters that should be disclosed but have not been disclosed

HANGZHOU LANDSCAPING announced that the closing price of its stock on March 7 and March 10, 2025, had a cumulative deviation of over 20% in the price increase over two consecutive trading days. According to the relevant provisions of the "Shanghai Stock Exchange Trading Rules," this constitutes an abnormal fluctuation in stock trading. After the company conducted a self-examination and verified with the controlling shareholder and actual controller through written correspondence, as of the date of this announcement, the company has no significant matters or risk matters that should be disclosed but have not been disclosed

### Related Stocks

- [605303.CN](https://longbridge.com/en/quote/605303.CN.md)

## Related News & Research

- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [ERG: Executing on renewables growth, financial strength, and ESG leadership with 2026 targets confirmed](https://longbridge.com/en/news/297804998.md)
- [06:50 ETUnited Imaging secures CE mark for world's first dual wide-coverage CT family](https://longbridge.com/en/news/297901060.md)
- [Mass Megawatts develops salt rejection technology aiming to cut solar desalination costs to tap-water levels](https://longbridge.com/en/news/298062893.md)
- [Hartalega publishes presentation for 20th AGM](https://longbridge.com/en/news/297878053.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**